In the News

Clinically validated, scientifically proven fertility decision-support platform to serve more families

Tel Aviv – 20 November 2024 – FertilAI has raised $4.5 million co-led by Longevity Venture Partners and Redseed with additional investment from angel investors.

The company provides doctors with critical AI-driven patient insights to aide their clinical decision-making and optimize clinic workflow and efficiency, increasing daily treatments while maintaining the same level of high quality of care.

“The fertility market is growing at an unprecedented rate and becoming a pressing issue on a global scale,” said Raissa Hacohen, Managing Partner of Longevity Venture Partners. “We invested in FertilAI because the team’s expertise is uniquely suited to solve this market need and its platform has already demonstrated significant traction in the market.” 

FertilAI focuses on making fertility treatments easier and more effective for everyone. In 2024 alone, the product is being used globally by more than 50 physicians across 20,000+ patients.

The innovative AI-based Fertilane platform seamlessly integrates with clinic electronic medical records (EMRs) to improve predictability, clinical outcomes, and the patient experience throughout the fertility journey, from identifying optimal embryo transfer timing and optimizing decision-making throughout the stimulation cycle to ovulation tracking, supporting timed intercourse, and facilitating intrauterine insemination (IUI). Furthermore, the mobile patient app improves two-way communication between clinic and patients.

“We are absolutely delighted to support Rohi and his Tier 1 team on their mission to tangibly improve clinical outcomes with FertilAI’s next-generation algorithm,” said Helena Cavell, Principal at Redseed.

Offered as a unified platform, Fertilane provides physicians with a single address for individual patients, their treatment plans and recommendations, and all clinic-doctor-patient communications

“The investment is a significant validation of our mission and vision,” said Rohi Hourvitz, CEO of FertilAI. “Everything we do is focused on providing the opportunity to create families more quickly and affordably. We want patients to achieve pregnancy much earlier in the process, instead of struggling through multiple rounds of treatment at thousands of dollars each.”

The $4.5 million seed round will be invested in market expansion, personnel, and reinforcing R&D efforts, allowing the company to deliver solutions for better patient care throughout the entire fertility journey.

About FertilAI

FertilAI optimizes the fertility journey for healthcare providers and patients alike. Its mission is to bring advanced, clinically proven AI technology to enhance care.  The FertilAI scientifically validated clinical decision-support platform enhances fertility treatment and contributes to improved outcomes. FertilAI provides a patient-focused mobile app that connects with clinics’ electronic medical record (EMR) platform focusing on improving patient communication. For more information, visit www.fertilai.com.

Media Contact
Amy Kenigsberg
 K2 Global Communications
 https://k2-gc.com/
 amy@k2-gc.com
 tel: +972-9-794-1681 (+2 GMT)
 mobile: +972-524-761-341
 U.S.: +1-913-440-4072 (+7 ET)